Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Neurocrine Biosciences (NBIX) over the last 15 years, with Q3 2025 value amounting to -$3.4 million.

  • Neurocrine Biosciences' Gains from Investment Securities changed N/A to -$3.4 million in Q3 2025 from the same period last year, while for Dec 2025 it was $259.2 million, marking a year-over-year decrease of 4384.75%. This contributed to the annual value of $271.6 million for FY2024, which is 3525.9% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Gains from Investment Securities of -$3.4 million as of Q3 2025.
  • Neurocrine Biosciences' 5-year Gains from Investment Securities high stood at $262.6 million for Q4 2024, and its period low was -$14.2 million during Q2 2023.
  • Over the past 4 years, Neurocrine Biosciences' median Gains from Investment Securities value was $16.0 million (recorded in 2021), while the average stood at $92.0 million.
  • Examining YoY changes over the last 5 years, Neurocrine Biosciences' Gains from Investment Securities showed a top increase of 3195.98% in 2024 and a maximum decrease of 3195.98% in 2024.
  • Neurocrine Biosciences' Gains from Investment Securities (Quarter) stood at $16.0 million in 2021, then skyrocketed by 1143.75% to $199.0 million in 2023, then skyrocketed by 31.96% to $262.6 million in 2024, then plummeted by 101.29% to -$3.4 million in 2025.
  • Its Gains from Investment Securities stands at -$3.4 million for Q3 2025, versus $262.6 million for Q4 2024 and $199.0 million for Q4 2023.